twice and they didn't take. basically, phiii's enroll many more patients than phii's. statistically, this provides more accurate and comprehensive data. in pharmaceutical trials, safety and efficacy, for example. also, in the case of some trials, the phiii's target a subpopulation of the patients who were enrolled in the phii's. for example, based on the phii, gale has targeted early stage, n+, low to intermediate her2 expression breast cancer. the fda website provides information regarding clinical trials, in general. hope this helps.
Thanks for the reply. I understand now getting a much larger sample to show the same success rate as in phase II did with a smaller sample. I assuming if everything works as well as it did in phase II with a larger sample in phase III we could see a rise in the percentage of people with no remission. That would be great saving lives and making longs cash. I like that idea.